T. Rowe Price Associates
NVAX icon

T. Rowe Price Associates’s Novavax NVAX Stock Holding History

T. Rowe Price Associates’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Buy
180,468
+22,524
+14% +$204K ﹤0.01% 1968
2025
Q4 		$1.06M Sell
157,944
-33,122
-17% -$250K ﹤0.01% 2062
2025
Q3 		$1.66M Buy
191,066
+7,921
+4% +$61.6K ﹤0.01% 1818
2025
Q2 		$1.15M Buy
183,145
+4,008
+2% +$26.5K ﹤0.01% 1923
2025
Q1 		$1.15M Buy
179,137
+99,073
+124% +$819K ﹤0.01% 1883
2024
Q4 		$644K Sell
80,064
-10,159
-11% -$97.9K ﹤0.01% 2173
2024
Q3 		$1.14M Buy
90,223
+17,667
+24% +$228K ﹤0.01% 1920
2024
Q2 		$919K Buy
72,556
+16,491
+29% +$166K ﹤0.01% 1929
2024
Q1 		$269K Buy
56,065
+8,128
+17% +$37.7K ﹤0.01% 2483
2023
Q4 		$231K Sell
47,937
-5,258
-10% -$32.2K ﹤0.01% 2485
2023
Q3 		$386K Buy
53,195
+202
+0.4% +$1.61K ﹤0.01% 2236
2023
Q2 		$394K Sell
52,993
-4,838
-8% -$38K ﹤0.01% 2243
2023
Q1 		$401K Buy
57,831
+11,693
+25% +$108K ﹤0.01% 2204
2022
Q4 		$474K Buy
46,138
+555
+1% +$9.79K ﹤0.01% 2153
2022
Q3 		$830K Buy
45,583
+2,473
+6% +$107K ﹤0.01% 1859
2022
Q2 		$2.22M Sell
43,110
-1,167
-3% -$60.4K ﹤0.01% 1579
2022
Q1 		$3.26M Sell
44,277
-173,080
-80% -$15.4M ﹤0.01% 1556
2021
Q4 		$31.1M Sell
217,357
-248,562
-53% -$42.7M ﹤0.01% 1165
2021
Q3 		$96.6M Buy
465,919
+76,195
+20% +$16.8M 0.01% 782
2021
Q2 		$82.7M Sell
389,724
-433,044
-53% -$79.3M 0.01% 857
2021
Q1 		$149M Buy
822,768
+476,750
+138% +$95M 0.01% 645
2020
Q4 		$38.6M Buy
346,018
+154,858
+81% +$16.5M ﹤0.01% 1045
2020
Q3 		$20.7M Sell
191,160
-37,544
-16% -$4.57M ﹤0.01% 1149
2020
Q2 		$19.1M Buy
+228,704
New +$8.75M ﹤0.01% 1157
2019
Q1 		– Sell
-140,542
Closed -$5.17M – 2558
2018
Q4 		$5.17M Buy
+140,542
New +$5.45M ﹤0.01% 1400
2017
Q2 		– Sell
-2,285
Closed -$58K – 2573
2017
Q1 		$58K Hold
2,285
– – ﹤0.01% 2533
2016
Q4 		$58K Hold
2,285
– – ﹤0.01% 2512
2016
Q3 		$95K Sell
2,285
-1,171,871
-100% -$151M ﹤0.01% 2450
2016
Q2 		$171M Buy
1,174,156
+2,212
+0.2% +$254K 0.04% 447
2016
Q1 		$121M Buy
1,171,944
+34,994
+3% +$3.75M 0.03% 506
2015
Q4 		$191M Buy
1,136,950
+71,432
+7% +$11M 0.04% 412
2015
Q3 		$151M Buy
1,065,518
+72,195
+7% +$16.2M 0.03% 467
2015
Q2 		$221M Sell
993,323
-54
-0% -$9.49K 0.05% 421
2015
Q1 		$164M Buy
993,377
+374,522
+61% +$60.8M 0.03% 479
2014
Q4 		$73.4M Buy
618,855
+23,280
+4% +$2.43M 0.02% 711
2014
Q3 		$49.7M Buy
595,575
+84,840
+17% +$7.67M 0.01% 833
2014
Q2 		$47.2M Buy
510,735
+351,045
+220% +$30.9M 0.01% 884
2014
Q1 		$14.5M Sell
159,690
-53,823
-25% -$6.01M ﹤0.01% 1201
2013
Q4 		$21.9M Buy
213,513
+278
+0.1% +$19.6K 0.01% 1078
2013
Q3 		$13.5M Buy
213,235
+210,860
+8,878% +$11.9M ﹤0.01% 1189
2013
Q2 		$97K Buy
+2,375
New +$103K ﹤0.01% 2344

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's NVAX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Novavax (NVAX) stake by 14% in Q1 2026, buying an estimated $204K and bringing the position to 180,468 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1968.

T. Rowe Price Associates first reported a position in NVAX in Q2 2013 and has held it in 41 quarters since. The position peaked at $221M in Q2 2015. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • T. Rowe Price Associates held 180,468 shares of Novavax worth $1.47M as of Q1 2026.
  • T. Rowe Price Associates bought 22,524 Novavax shares in Q1 2026, an estimated $204K.
  • Novavax made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1968 holding.
  • T. Rowe Price Associates first reported a position in Novavax in Q2 2013 and has held it in 41 quarters since.
  • T. Rowe Price Associates's Novavax position peaked at $221M in Q2 2015.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.